SG/CALL/ROCHE GS/250/0.1/20.06.25 Stock

Warrant

DE000SW2DH49

Delayed Deutsche Boerse AG 08:47:02 2024-06-17 am EDT
1.59 EUR -4.79% Intraday chart for SG/CALL/ROCHE GS/250/0.1/20.06.25
Current month+75.79%
1 month+128.77%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-17 1.59 -4.79%
24-06-14 1.67 +1.21%
24-06-13 1.65 +17.02%
24-06-12 1.41 +0.71%
24-06-11 1.4 +3.70%

Delayed Quote Deutsche Boerse AG

Last update June 17, 2024 at 08:47 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Société Générale Société Générale
WKN SW2DH4
ISINDE000SW2DH49
Date issued 2023-08-17
Strike 250 CHF
Maturity 2025-06-20 (368 Days)
Parity 10 : 1
Emission price 3.15
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.34
Lowest since issue 0.52
Delta0.45x
Omega 7.064
Premium8.63x
Gearing15.77x
Moneyness 0.9776
Difference Strike 4.35 CHF
Difference Strike %+1.74%
Spread 0.06
Spread %3.64%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus